STOCK TITAN

Nuwellis YTD revenue grows 13%, gross margin hits 72%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Nuwellis, Inc. (NUWE) posted an updated November 2026 investor presentation. It reports YTD 2026 revenue growth of 13% versus the prior-year period and a gross margin of 72%, compared with 59% in the prior year. Cash was $8.3 million as of September 30, 2026, with a stated runway through Q2 2027. Pediatrics represented approximately 46% of YTD 2026 revenue, and the presentation lists 47 leading U.S. children’s hospital accounts.

Nuwellis said it submitted a 510(k) in November 2026 to expand the Aquadex weight indication from >20 kg to >5 kg. Listed target milestones include Zorro-Flow commercialization in Q1 2027, SmartView in H1 2027, Pressure IQ and ClarityPRIME in H2 2027, and multiple filters from Q4 2027 to Q1 2028. ClarityPRIME and Vivian are under development, and ClarityPRIME is not FDA cleared. The presentation describes a potential $4.4 billion U.S. market across its platform and future products; it cautions that forward-looking statements are not guarantees and actual results may differ materially.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointYTD revenue growth reached 13% versus the prior-year period.
  • Moderate pointYTD gross margin was 72%, compared with 59% in the prior year.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
YTD revenue growth 13% YTD 2026 versus the prior-year period
Gross margin 72% YTD 2026, compared with 59% in the prior year
Cash $8.3 million As of September 30, 2026
Cash runway Through Q2 2027 Company presentation
Pediatric share of revenue Approximately 46% YTD 2026
Children’s hospital accounts 47 accounts Leading U.S. children’s hospitals
Potential U.S. platform market $4.4 billion Total platform potential opportunity across current platform and future products
Aquadex pediatric weight indication From >20 kg to >5 kg 510(k) submission reported in November 2026
ultrafiltration technical
"low-volume ultrafiltration designed for critically ill patients"
Ultrafiltration is a process that separates small particles and liquids from larger molecules or substances using a filter with tiny pores. It is often used in water treatment and medical applications to remove impurities or excess fluids. For investors, understanding ultrafiltration is important because innovations or changes in this technology can impact industries focused on clean water, healthcare, and filtration products.
510(k) regulatory
"FDA 510(k) submission for pediatric indication expansion"
A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.
ECMO medical
"Enables use with ECMO circuits"
Extracorporeal membrane oxygenation (ECMO) is a hospital-based life support system that temporarily takes over the job of the heart and lungs by circulating blood outside the body through a machine that adds oxygen and removes carbon dioxide. Think of it as an external engine that keeps oxygen flowing when a patient’s own organs are failing. For investors, ECMO signals high-cost, specialized care, drives demand for devices, training and disposables, and can affect hospital capacity, reimbursement and supplier revenue.
CRRT medical
"neonatal + small-child CRRT"
Continuous Renal Replacement Therapy (CRRT) is a hospital treatment that uses a machine to slowly and continuously filter a patient’s blood when the kidneys have failed, similar to a home water filter running all day instead of a quick rinse. For investors, CRRT signals demand for critical-care equipment, supplies and specialized staffing, and changes in its use or reimbursement can affect revenues and costs for medical-device makers, hospitals and dialysis service providers.
CVVH medical
"Integrated UF, CVVH, and CVVHD therapies"
CVVHD medical
"Integrated UF, CVVH, and CVVHD therapies"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financial metrics did NUWE report for YTD 2026?

Nuwellis reported 13% YTD revenue growth versus the prior-year period and a 72% YTD gross margin, compared with 59% in the prior year.

How much cash did NUWE have, and what runway did it report?

Nuwellis reported $8.3 million in cash as of September 30, 2026, and a cash runway through Q2 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2026

Nuwellis, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-35312
No. 68-0533453
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

12988 Valley View Road, Eden Prairie, MN 55344
(Address of Principal Executive Offices) (Zip Code)

(952) 345-4200
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NUWE
NASDAQ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 7.01
Regulation FD Disclosure.
 
On November 17, 2026, Nuwellis, Inc. (the “Company”) posted an updated corporate presentation to its website at https://nuwellis.com/investors/, which the Company may use from time to time in presentations, investor communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.

Information contained on or accessible through any website reference in the corporate presentation is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the corporate presentation is as inactive textual references only.

The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Forward-Looking Statements

Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

Number
 
Description
99.1
 
Corporate Presentation, dated November 17, 2026
104
 
Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 17, 2026
NUWELLIS, INC.
   
 
By:
/s/ Michael K. McCormick
     
 
Name:
Michael K. McCormick
 
Title:
President and Chief Executive Officer




Exhibit 99.1

 November 2026  INVESTOR PRESENTATION  NASDAQ: NUWE 
 

 NASDAQ: NUWE  Forward-Looking Statements  This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the future that are intended to be covered by the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, all forward-looking statements are management’s present expectations and are not guarantees of future events and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “plan,” “predict,” “potential,” “project,” “promising,” “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “milestone,” and similar expressions and variations thereof. Various factors could cause actual results to differ materially from these statements including our ability to execute on our commercial strategy and to grow our Aquadex® business, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our expectations regarding anticipated synergies with and benefits of the Aquadex business, our business strategy, market size, potential growth opportunities and the other risks set forth under the caption “Risk Factors” and elsewhere in our periodic and other reports filed with the U.S.  Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and  subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this presentation, and we undertake no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Although the Company believes that the forward-looking statements are reasonable and based on information currently available, it can give no assurances that the Company’s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.  2 
 

 NASDAQ: NUWE See Appendix for Market Opportunity sources.  Investment Highlights  3  Best-in-class ultrafiltration technology  Aquadex® is a clinically proven system for precise, predictable fluid removal reducing hospital readmissions and improving outcomes  Streamlined solution that is cost-effective, workflow-friendly, and backed by comprehensive clinical support  Expanding our platform into new indications and leveraging our commercial infrastructure through partnerships  Planned label expansion and new products in development broaden our offering  Recent partnerships leverage sales team and expand our cardiorenal solutions  Addressing a large and growing market opportunity  Total platform potential opportunity exceeds $4.4 billion in the U.S.  Accelerating growth in pediatric care  Adopted by leading children’s hospitals  Pediatrics patients represents approximately 50% of revenues  Improving financial metrics with revenue growth and expanding margins  YTD revenue growth of 13% over the prior-year period  YTD gross margins improved to 72% compared to 59% in the prior-year period  Cash runway through Q2 2027 supports execution of near-term growth initiatives 
 

 Fluid Overload Drives Mortality and Hospitalizations  4  Higher ICU Mortality  Fluid overload is associated with significantly increased 90-day mortality in critically ill ICU patients2  Increased Pediatric Mortality  Fluid overload is linked to substantially higher mortality in critically ill children3-4  Key Driver of Hospitalizations  ~90% of HF hospitalizations are associated with symptoms of fluid overload5  Fluid overload is a leading cause of costly hospital readmission 30 days following cardiac surgeryrgery1  Pediatric Critical Care Heart Failure  1. Iribarne A, et al. Ann Thorac Surg. 2014; 98(4): 1274-80. 2. Vaara ST et al. Crit Care.2012; 16: 1-11. 3 Sutherland SM, et al. Am J Kidney Disease. 2010; 5(2): 316-25. 4 Gillespie RS, et al. Ped Nephro. 2004; 19(12): 1394-99. 5  NASDAQ: NUWE Costanzo MR, et al. JACC. 2017 May 16;69(19):2428-2445. 
 

 NASDAQ: NUWE Sources: See Appendix  $4.4B Addressable U.S. Market Opportunity  5  Nuwellis current platform and future products collectively address a large market opportunity across five segments  Critical Care  Inpatient HF  Outpatient HF  Pediatrics  Fluid Monitoring  $1B  $1B  $787M  $178M  $1.4B 
 

 6  Our Solution  Aquadex®  A clinically proven therapy for precise, predictable fluid removal1  Low-volume ultrafiltration designed for critically ill patients  Allows controlled fluid removal when  diuretics fail or are ineffective  Adopted in ICU, cardiac surgery, and pediatric critical care programs  1Pinney, S et. al., J AM Coll Cardiol HF, 2025, ISSN 2213-1779 https://doi.org/10.1016/j.jchf.2024.11.018 
 

 NASDAQ: NUWE  Aquadex System: Predictable and Precise Fluid Removal  Filtered blood returns to the patient via the infusion line  5  Blood is taken from the patient via the withdrawal line using proprietary catheter technology  1  The blood is pushed through the filter by the blood pump  (0-40 ml per minute)  2  The ultrafiltration pump withdraws fluid across the filter membrane using negative pressure  Hematocrit sensor monitors preset hematocrit limits  3  Ultrafiltration pump can pull 0-500 ml of fluid per hour  4  7 
 

 NASDAQ: NUWE  Aquadex System: High-Margin Recurring Revenue Model  8  One-time CapEx purchase  Price point: high-value  Flexible acquisition models: purchase, lease or rental  Single-use for every  treatment  High-margin  Increasing utilization as adoption spreads  Aquadex Console Capital Equipment  Disposables Recurring Revenue 
 

 NASDAQ: NUWE  Commercial Execution Demonstrating Broad-Based Growth  9  Broad Clinical Coverage  Pediatric - 26% growth* in pediatric  nephrology & critical care  Critical Care – 7% growth* in ICU/intensivists & cardiac surgery  Heart Failure – 9% growth* in heart failure cardiology  *Nine months ended 9/30/26 YOY US revenue growth  Complex Therapy Sales Capability  Experienced sales and clinical teams  Expertise navigating multi-department adoption  Ability to establish new therapy programs  Performance  13% YTD revenue growth vs. prior year  72% gross margin YTD 2026, up from 59% in the prior year  ~135 leading U.S. hospital accounts, representing approximately 10% of target hospitals**  Multiple growth opportunities within existing accounts across pediatrics, critical care, and heart failure  **US News Report: https://health.usnews.com/best-hospitals/pediatric-rankings 
 

 NASDAQ: NUWE  Pediatric Leadership Driving Future Growth  10  Future Pediatric Product Offering  Established adoption creates a foundation for expanded indications and next-generation therapies  Installations in 47 Leading U.S. Children’s Hospitals*  Established clinical footprint across pediatric critical care settings  Providing precise, gentle fluid removal for critically ill children who require controlled ultrafiltration in pediatric critical care settings  Submitted 510(k) to expand Aquadex weight indication to >5kg from >20kg to facilitate broader adoption  Development of Vivian as the next-generation pediatric renal  support platform supporting patients as small as 2.5kg  *US News Report: https://health.usnews.com/best-hospitals/pediatric-rankings 
 

 NASDAQ: NUWE  Critical Care: Addressing Fluid Overload Following Cardiac Surgery  11  The Problem  Cardiac surgery can require significant fluid administration, contributing to post-operative fluid overload1  1 DeVore A, et al. Curr Treat Opts Cardiovasc Med. 2014; 16(2):283. 2 Bundgaard-Nielsen M, et al. Acta Anaesthesiol Scand 2009; 53:843-851. 3 Wiedemann HP, et al. N Engl J Med.  2006, 354:2564-75. 4 Stein A, et al. Critical Care. 2012; 16(R99):1-9. 5 Miller TE, et al. Can J Anesthes. 2015; 62:158-68.  Aquadex Solution  Simple, predictable fluid removal when precise volume management is needed  Clinical Value  Reduces time to be extubated2,3  Shortens time in post op care and ICU length of stay3,4  Improves outcomes2-5  Predictable Control with Less Complexity 
 

 NASDAQ: NUWE  Heart Failure: Breaking the Cycle of Fluid Overload and Readmission  12  The Problem  Persistent congestion drives repeat hospitalization  Aquadex Solution  Precise, predictable fluid removal – for patients with fluid overload when diuretics are inadequate  60% Reduction in HF Events at 30 days – Adjustable ultrafiltration vs. adjustable IV diuretics4  Reduces strain on the kidneys and improves long-term outcomes  1Gheorghiade M, et al. Eur Heart J Suppl. 2005; 7:B13-9. 2Premier Applied Sciences Database. 3Costanzo MR, et al. J Am Coll Cardiol. 2017, May 16; 69(19):2428-2445.  4Pinney SP, DeVita MV, Redfors B, et al. Ultrafiltration for Management of Decompensated Heart Failure: A Reappraisal of AVOID-HF. JACC Heart Fail. 2025;13(4):657-659. 
 

 NASDAQ: NUWE *ClarityPRIME is currently under development and is not FDA cleared.  Expanding Beyond Fluid Removal into Critical Care Solutions  13  Leveraging our ICU & pediatric commercial infrastructure to expand into adjacent monitoring and therapy markets  Current Commercial Engine Near-term Expansion Long-term Pediatric Upside  Enhancing capabilities with SmartView, High Flow and multiple filters  ClarityPRIME  Automated urine output and electrolyte monitoring for critical care  Precision fluid removal platform deployed  across ICU and pediatric centers  Co-Promotion and Distribution for AtriAmp®  Cardiac Rhythm Monitoring  Next-generation pediatric renal  support platform  Distribution for Zorro-Flow neonate non-invasive urine collection system 
 

 NASDAQ: NUWE  Technologies and expanded applications described are under development and subject to applicable regulatory requirements.  R&D Expanding Aquadex Capabilities to Extend Platform Use  14  SmartView Provides Real-time Insights  Pressure IQ Expands Aquadex Performance and Versatility  Multiple Filters For Critical Care  Adapted to run adsorption and other modality filters  Applications include drug overdose/poisoning, chemotherapy filtration, autoimmune disease, sepsis  $280M potential market opportunity  Optimizes therapy and supports decisions  Designed to seamlessly integrated with EMR and hospital systems  Designed to simplify workflows and improves productivity  Intelligently senses and adapts to changing inlet pressures  Reduces unnecessary alarms and therapy interruptions  Enables higher blood flow to support  enhanced filtration performance  Enables use with ECMO circuits to expand market opportunity  Smarter Technology. Expanded Capabilities. More Patients. One Aquadex Platform. 
 

 NASDAQ: NUWE  AtriAmp Advances Nuwellis' Expansion Strategy  A capital-efficient opportunity to broaden Nuwellis' product portfolio and leverage existing hospital relationships  15  CLINICAL VALUE  AtriAmp improves visibility into postoperative arrhythmias in adult and pediatric cardiac surgery patients  ECG alone  ECG with AtriAmp Signal  A clearer atrial signal, continuously at the bedside  STRATEGIC VALUE TO NUWELLIS  Clinical and Portfolio Adjacency Expands our product portfolio and Strengthens customer relationships  Commercial Leverage  Expands engagement with established hospital  relationships in pediatric, cardiac surgery, & critical care  Revenue Expansion  Single-patient-use device creates recurring revenue potential with limited incremental commercial investment  Exclusive Distribution Opportunity  U.S. rights (ex-NY) · Recurring product revenue  Performance Criteria  Pre-established milestones evaluated  6-Month Co-Promotion Pilot  ~11 Western states · Current sales team 
 

 NASDAQ: NUWE  1https://www.nature.com/articles/s41372-023-01834-x  Zorro-Flow® Expands Nuwellis' Pediatric Cardiorenal Portfolio  Exclusive U.S. distribution rights leverage established pediatric hospital relationships to create new recurring revenue opportunities.  16  CLINICAL VALUE  A non-invasive urine collection system for neonates and  small children to avoid difficult catheterizations  Enables accurate urine output measurement and monitoring  Up to 24-hour use to minimize provider time and effort  Clean samples for urinalysis  Urine output assessment is essential to detect acute kidney injury  STRATEGIC VALUE TO NUWELLIS  Strengthens Position in Pediatrics Addresses clinical need for urine output and AKI assessment without limitations of current solutions  Leverages existing call point  Leverages established PICU, CVICU and pediatric nephrology relationships to accelerate market entry  Recurring revenue growth  Daily single-patient-use devices create incremental revenue potential and additional customer touchpoints  350,0001  Neonatal ICU admissions annually in the U.S.  Launch Q1 2027  Planned full U.S. commercialization 
 

 NASDAQ: NUWE  17  1 Addresses a Critical Need in Cardiac Surgery & Critical Care  Enters a High-growth, Underpenetrated Market  Fits Directly Into Our Existing Sales Channel  Real-time urine output and electrolyte data are essential for early detection of AKI.  Targets the emerging automated urine monitoring segment within the broader urinalysis and critical care monitoring market.  RMS price point ($2,500 console;  $60–80 kits) aligns with Aquadex’s critical care sales and our common call point.  Commercial Launch Expected in 2H 2027  2  3  *ClarityPRIME is currently under development and is not FDA cleared.  ClarityPRIME* System Expands Nuwellis into Smart Fluid Monitoring 
 

 18  Introducing  Vivian  Developing our dedicated pediatric solution  Currently in development and supported  by a $3M NIH grant.  Ultra-low ECV (29–67 mL) for neonatal  + small-child CRRT  Engineered for patients as small as 2.5kg with unique Hematocrit and SVO2 sensor safety features  Integrated UF, CVVH, and CVVHD therapies in one platform  *Vivian is currently under development and is not FDA cleared. 
 

 NASDAQ: NUWE  19  Established Platform with Multiple Growth Drivers  Commercial  Momentum  +13%  YTD 2026 revenue growth versus prior-year  72% YTD 2026 gross margin, up from 59% in YTD 2025  Hospital  Opportunity  ~135  Active hospital accounts  Installed in ~10% of target hospitals  Significant opportunity to increase market penetration and scale utilization  Pediatric  Leadership  47  Leading U.S. children’s  hospital accounts  ~46% of YTD 2026 revenue  Potential Aquadex label expansion to >5 kg pediatric patients to broaden market  Broadening product portfolio on pediatrics  Aquadex  Innovation  Multiple  Expansion capabilities to extend platform in 2027  SmartView  Pressure IQ  New filters for critical care  Portfolio  Expansion  4  New product solutions with same call point  AtriAmp (currently offered)  Zorro-Flow (2027)  ClarityPRIME (2027) Vivian (2028/2029)  Growing Installed Base • Expanding Capabilities • Leveraging Commercial Infrastructure 
 

 NASDAQ: NUWE  Target Milestones  20  Target Date | Completed  Milestone  Q3 2026 | Aug. 2026  Strategic partnership/distribution agreement  Q4 2026 | Oct. 2026  Publication of ULTRA-Peds data in Pediatric Nephrology  Q4 2026 | Nov. 2026  FDA 510(k) submission for pediatric indication expansion to >5kg (from >20kg)  Q4 2026 | Nov. 2026  Additional strategic partnership/distribution agreement  H1 2027  Launch of SmartView for Aquadex  H2 2027  Launch of Pressure IQ for Aquadex  H2 2027  ClarityPRIME commercial launch  Q4 2027 - Q1 2028  Launch of multiple filters for Aquadex 
 

 NASDAQ: NUWE  Nuwellis Leadership Team  Over 200 years of combined experience in clinical practice and the medical device industry, including major tenures at J&J, Boston Scientific, Medtronic, and Abbott/St. Jude Medical  21  Ryan Marthaler  Vice President of Product Marketing and Business Development  Betsy Riemenschneider Regional Vice President of Sales  Carisa Schultz Chief Financial Officer  Kelsey Newell  Senior Director of Medical Affairs  Neil Ayotte  Sr. Vice President, General Counsel & Compliance  Officer  Kim Anderson  Vice President of Operations  Scott Campbell Regional Vice President of Sales  David Lerner  Vice President of Research  Mike McCormick President and CEO 
 

 NASDAQ: NUWE * See SEC filings for Preferred Stock terms and anti-dilution provisions.  Financial Highlights  22  Pediatrics  ~50%  Revenue Mix  $6.6M YTD Q3 26  Heart Failure  ~26%  Critical Care  ~24%  13% YTD 2026 revenue growth versus the prior-year period  Capitalization  as of September 30, 2026  Common Equivalents  Common Stock  540,912  Preferred Stock*  2,623  Warrants  232,443  Options  183  Fully Diluted Shares Outstanding  776,161  Cash  (as of September 30, 2026)  $8.3 million  Cash runway  Through 2Q 2027  Expected cash runway to support near-term growth initiatives  Focused expense management and capital allocation to reduce cash burn 
 

 Contact Details  Investor Relations: CORE IR  Yvonne Briggs ir@nuwellis.com  Media Inquiries: CORE PR  Kati Waldenburg media@nuwellis.com 
 

 NASDAQ: NUWE  Appendix  Market Size Sources  Heart Failure – Inpatient  Incidence of HF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/  Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445  Insufficient diuretic response: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.115.002370?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  Heart Failure – Outpatient  Incidence of HF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/  Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445  Diuretic resistance rate: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.115.002370?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  Critical Care  VADs: https://www.grandviewresearch.com/industry-analysis/ventricular-assist-devices-market  CABG: https://www.grandviewresearch.com/industry-analysis/coronary-artery-bypass-graft-cabg-market  Valves: https://idataresearch.com/over-182000-heart-valve-replacements-per-year-in-the-united-states/  Liver Transplants: https://www.healthline.com/health/liver-transplant-survival  Liver Disease: https://www.ncbi.nlm.nih.gov/pubmed/25291348  Kidney Disease: https://www.kidney.org/news/newsroom/factsheets/KidneyDiseaseBasics  Sepsis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557150/  ECMO: https://www.uclahealth.org/medical-services/heart/ecmo/research/statistics  Pediatrics  Renal Replacement/AKI: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789331/#:~:text=The%20hospitalized%20population%20at%20risk,are%20shown%20in%20Table%201  Heart Disease: https://www.cdc.gov/ncbddd/heartdefects/data.html#:~:text=Congenital%20heart%20defects%20are%20conditions,the%20United%20States%20each%20year  Pediatric Transplantations: https://www.organdonor.gov/about/donors/child-infant.html  Pediatric ECMO: https://www.ncbi.nlm.nih.gov/pubmed/23246046  24 
 


Filing Exhibits & Attachments

4 documents

Keep reading